PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
1 - 32 .
33 . A controlled release oral dosage form comprising:
a therapeutically effective amount of an opioid analgesic,
from about 10 ng to 275 mg of an opioid antagonist, and
particles consisting of a gelling agent, one or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid, and one or more additional pharmaceutically acceptable excipient(s),
wherein the gelling agent is releasable from said particles and a solubilized mixture having a viscosity unsuitable for injection is formed when the dosage form is crushed and dissolved in from about 1 to about 5 ml of water,
a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, and
the gelling agent is polyethylene oxide.
34 . The dosage form of claim 33 , wherein the viscosity is at least 60 Cp.
35 . The dosage form of claim 33 , wherein the viscosity is from 10 cP to 60 cP.
36 . The dosage form of claim 33 , wherein the dosage form provides pain relief for at least about 12 hours when orally administered intact to a human patient.
37 . The dosage form of claim 33 , wherein the opioid analgesic is selected from the group consisting of oxycodone, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, pharmaceutically acceptable salts thereof, and mixtures thereof.
38 . The dosage form of claim 38 , wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.
39 . The oral dosage form of claim 33 , wherein the opioid antagonist comprises naloxone or a pharmaceutically acceptable salt thereof.
40 . A controlled release oral dosage form comprising:
a therapeutically effective amount of an opioid analgesic selected from the group consisting of oxycodone, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, pharmaceutically acceptable salts thereof, and mixtures thereof,
an opioid antagonist, and
particles consisting of a gelling agent, one or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid, and one or more additional pharmaceutically acceptable excipient(s),
wherein the gelling agent is releasable from said particles in an effective amount such that syringeability is hindered when the dosage form is crushed and dissolved in from about 1 to about 5 ml of water,
a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, and
the gelling agent is polyethylene oxide.
41 . The dosage form of claim 40 , wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.
42 . The dosage form of claim 40 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.
43 . The dosage form of claim 40 , wherein the opioid analgesic is morphine or a pharmaceutically acceptable salt thereof.
44 . The dosage form of claim 40 , wherein the viscosity is at least 60 Cp.
45 . The dosage form of claim 40 , wherein the opioid antagonist comprises naltrexone or a pharmaceutically acceptable salt thereof.
46 . The dosage form of claim 40 , wherein the dosage form provides pain relief for at least about 12 hours when orally administered intact to a human patient.
47 . The dosage form of claim 46 , wherein the dosage form provides pain relief for about 24 hours when orally administered intact to the human patient.
48 . The dosage form of claim 42 , wherein the dosage form provides pain relief for at about 24 hours when orally administered intact to the human patient.
49 . A controlled release oral dosage form comprising:
a therapeutically effective amount of an opioid analgesic selected from the group consisting of oxycodone, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, pharmaceutically acceptable salts thereof, and mixtures thereof,
an opioid antagonist, and
particles consisting of a gelling agent, one or more pharmaceutically acceptable hydrophobic material(s) selected from the group consisting of cellulose polymers, acrylic polymers, polylactic acid, polyglycolic acid and a co-polymer of the polylactic acid and polyglycolic acid, and one or more additional pharmaceutically acceptable excipient(s),
wherein the gelling agent is releasable from said particles in an effective amount such that the dosage form forms a gel that cannot be drawn into an insulin syringe without picking up pockets of air when the dosage form is crushed and dissolved in from about 1 to about 5 ml of water,
a weight ratio of the gelling agent to the opioid analgesic is from about 1:40 to about 40:1, and
the gelling agent is polyethylene oxide.